This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NK vs. ADPT, IOVA, NVAX, VIR, REPL, AVXL, LENZ, VECT, VALN, and IMTXShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Vir Biotechnology (VIR), Replimune Group (REPL), Anavex Life Sciences (AVXL), LENZ Therapeutics (LENZ), VectivBio (VECT), Valneva (VALN), and Immatics (IMTX). These companies are all part of the "medical" sector. NantKwest vs. Adaptive Biotechnologies Iovance Biotherapeutics Novavax Vir Biotechnology Replimune Group Anavex Life Sciences LENZ Therapeutics VectivBio Valneva Immatics Adaptive Biotechnologies (NASDAQ:ADPT) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do analysts prefer ADPT or NK? Adaptive Biotechnologies currently has a consensus target price of $9.40, suggesting a potential upside of 23.18%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, ADPT or NK? Adaptive Biotechnologies has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Does the media favor ADPT or NK? In the previous week, Adaptive Biotechnologies had 7 more articles in the media than NantKwest. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 0 mentions for NantKwest. Adaptive Biotechnologies' average media sentiment score of 0.78 beat NantKwest's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Overall Sentiment Adaptive Biotechnologies Positive NantKwest Neutral Does the MarketBeat Community believe in ADPT or NK? NantKwest received 175 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. However, 57.99% of users gave Adaptive Biotechnologies an outperform vote while only 49.55% of users gave NantKwest an outperform vote. CompanyUnderperformOutperformAdaptive BiotechnologiesOutperform Votes9857.99% Underperform Votes7142.01% NantKwestOutperform Votes27349.55% Underperform Votes27850.45% Do insiders & institutionals have more ownership in ADPT or NK? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, ADPT or NK? NantKwest has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M6.34-$159.49M-$1.09-7.00NantKwest$40K8,091.53-$65.79M-$0.70-4.23 Is ADPT or NK more profitable? Adaptive Biotechnologies has a net margin of -89.12% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-89.12% -64.65% -26.45% NantKwest -76,658.58%-56.06%-46.93% SummaryAdaptive Biotechnologies beats NantKwest on 10 of the 18 factors compared between the two stocks. Remove Ads Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.66M$2.93B$5.52B$7.84BDividend YieldN/A1.55%5.35%4.04%P/E Ratio-4.1730.1723.3718.65Price / Sales8,091.53401.00364.5487.34Price / CashN/A168.6838.1634.64Price / Book2.413.656.634.11Net Income-$65.79M-$72.06M$3.20B$247.10M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$2.96-1.7%N/A-43.9%$323.66M$40,000.00-4.17160High Trading VolumeADPTAdaptive Biotechnologies3.9798 of 5 stars$7.43-3.1%$9.40+26.5%+141.8%$1.10B$178.96M-6.82790IOVAIovance Biotherapeutics4.2676 of 5 stars$3.33-6.5%$20.25+508.1%-77.1%$1.09B$164.07M-2.23500NVAXNovavax3.638 of 5 stars$6.41-8.4%$18.00+180.8%+29.0%$1.03B$682.16M-2.841,990VIRVir Biotechnology3.6616 of 5 stars$6.48-3.3%$35.67+450.4%-39.4%$888.69M$63.71M-1.65580REPLReplimune Group3.6623 of 5 stars$9.75-6.2%$19.43+99.3%+8.7%$750.90MN/A-3.18210Positive NewsAVXLAnavex Life Sciences3.6729 of 5 stars$8.58-1.6%$44.00+412.8%+59.8%$729.85MN/A-15.6040Analyst ForecastNews CoveragePositive NewsGap DownLENZLENZ Therapeutics1.9089 of 5 stars$25.71+0.3%$41.67+62.1%+23.8%$708.13MN/A-5.39110VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeVALNValneva1.8368 of 5 stars$6.71-7.6%$16.00+138.5%-11.9%$545.26M$169.58M-51.62700Analyst ForecastNews CoverageGap UpIMTXImmatics1.8034 of 5 stars$4.51-2.6%$16.67+269.5%-63.8%$538.30M$155.84M-6.83260Earnings ReportAnalyst ForecastAnalyst Revision Remove Ads Related Companies and Tools Related Companies ADPT Alternatives IOVA Alternatives NVAX Alternatives VIR Alternatives REPL Alternatives AVXL Alternatives LENZ Alternatives VECT Alternatives VALN Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NK) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NK Stock Free NK Stock Alerts